Update on Risankizumab for Psoriasis

Purpose of Review This review highlights the latest data on risankizumab, including efficacy and safety data from recent clinical trials. Recent Findings In multiple phase 3 clinical trials, risankizumab was shown to be safe and efficacious. Risankizumab demonstrated superior efficacy to leading active comparators for the induction and maintenance of clear skin and was shown to have a safety profile similar to other biologic therapies currently on the market. Summary Targeted biologic medications for plaque psoriasis have provided insight into the complex immune pathways that are now understood to lead to the development of several autoimmune diseases including plaque psoriasis. Risankizumab, a novel, fully human monoclonal antibody against the IL-23p19 subunit, is currently under investigation for the treatment of moderate-to-severe plaque psoriasis and shows promise to provide complete and lasting skin clearance with convenient dosing for patients. Future studies are needed to explore the long-term safety and efficacy of risankizumab beyond 5 years of therapy.